Sign in Subscribe
COVID-19 vaccines

FDA Vaccine Advisers to Meet on Johnson & Johnson's Single-Dose COVID-19 Vaccine

Strategic Insights

— 1 min read

US Food and Drug Administration vaccine advisers will meet Friday to discuss the potential emergency authorization of Johnson & Johnson's single-dose coronavirus vaccine. The vaccine has shown to be 66% effective in preventing moderate to severe COVID-19 disease and 85% effective in preventing severe disease. The FDA has already considered the advanced clinical trial testing data presented by Janssen and found it to be safe and effective. The meeting is a crucial step in a process that could lead to the vaccine's rollout as early as next week.

Key Takeaways:

  • The FDA has already considered the advanced clinical trial testing data presented by Janssen and found it to be safe and effective.
  • Johnson & Johnson's single-dose vaccine has shown to be 66% effective in preventing moderate to severe COVID-19 disease and 85% effective in preventing severe disease.
  • The vaccine did not result in any deaths from COVID-19 in the clinical trials.
  • The White House has promised to begin distributing the vaccine immediately, with 2 million doses going to states and the rest directly to pharmacies and community health centers.
  • The federal government expects to have up to 4 million doses of Johnson & Johnson vaccine available on the first day.
  • Johnson & Johnson has promised to ramp up production to deliver 20 million doses by the end of March and 100 million doses by the end of June.

Statistics:

  • The Johnson & Johnson vaccine is 66% effective in preventing moderate to severe COVID-19 disease 28 days after immunization (Johnson & Johnson data).
  • The vaccine is 85% effective in preventing severe disease (Johnson & Johnson data).
  • No one who received the vaccine died from COVID-19 in the clinical trials.
  • The White House expects to distribute 2 million doses of the vaccine to states immediately.
  • The federal government expects to have up to 4 million doses available on the first day.
  • Johnson & Johnson aims to deliver 20 million doses by the end of March and 100 million doses by the end of June.

Sources:

  • CNN
  • Maggie Fox

Read more